###begin article-title 0
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 89 92 <span type="species:ncbi:9606">Man</span>
Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man
###end article-title 0
###begin p 1
Conceived and designed the experiments: JKL AL DHM PMM. Performed the experiments: JKL AL LH JMW. Analyzed the data: JKL DHM LH DF PMM. Contributed reagents/materials/analysis tools: AL JMW BJ HJ JP GAF DK DF SLS LM PMM. Wrote the paper: JKL DHM PMM.
###end p 1
###begin p 2
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 275 278 275 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS</italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 418 422 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 739 740 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 860 867 860 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1037 1038 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1078 1082 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 0 15 <span type="species:ncbi:11082">West Nile virus</span>
###xml 17 20 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 110 113 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 329 332 <span type="species:ncbi:9606">man</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 644 647 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 877 880 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 902 907 <span type="species:ncbi:9606">human</span>
###xml 1155 1158 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1162 1168 <span type="species:ncbi:9606">humans</span>
West Nile virus (WNV) is a re-emerging pathogen that can cause fatal encephalitis. In mice, susceptibility to WNV has been reported to result from a single point mutation in oas1b, which encodes 2'-5' oligoadenylate synthetase 1b, a member of the type I interferon-regulated OAS gene family involved in viral RNA degradation. In man, the human ortholog of oas1b appears to be OAS1. The 'A' allele at SNP rs10774671 of OAS1 has previously been shown to alter splicing of OAS1 and to be associated with reduced OAS activity in PBMCs. Here we show that the frequency of this hypofunctional allele is increased in both symptomatic and asymptomatic WNV seroconverters (Caucasians from five US centers; total n = 501; OR = 1.6 [95% CI 1.2-2.0], P = 0.0002 in a recessive genetic model). We then directly tested the effect of this SNP on viral replication in a novel ex vivo model of WNV infection in primary human lymphoid tissue. Virus accumulation varied markedly among donors, and was highest for individuals homozygous for the 'A' allele (P<0.0001). Together, these data identify OAS1 SNP rs10774671 as a host genetic risk factor for initial infection with WNV in humans.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 754 758 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 1132 1136 1132 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 5 11 <span type="species:ncbi:9606">humans</span>
###xml 335 340 <span type="species:ncbi:9606">human</span>
###xml 472 487 <span type="species:ncbi:11082">West Nile virus</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 840 843 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 920 923 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 942 947 <span type="species:ncbi:9606">human</span>
###xml 1309 1312 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1325 1328 <span type="species:ncbi:9606">man</span>
When humans are exposed to infectious agents, the outcome may vary: some remain uninfected, some who become infected remain asymptomatic, and symptomatic individuals may develop clinical manifestations that vary in number and severity. Both host and environmental factors are thought to influence outcome. Here we show that a specific human mutation that results in reduced function in a known antiviral gene named OAS1 is associated with increased rate of infection with West Nile virus, a member of the flavivirus family. OAS1 codes for a component of the type I interferon signaling system; its homologue in mice has been shown previously to be important for flavivirus susceptibility. Individuals carrying two copies of the hypofunctional variant of OAS1 were found more frequently than expected among both asymptomatic and symptomatic WNV-positive individuals. To investigate further, we developed a novel model of WNV replication using human tonsil tissue in which high variability in replication was observed among donors. We found that the highest virus accumulation occurred in donors with two copies of the hypofunctional OAS1 variant. Together these data suggest that OAS1 activity may influence the probability of initial infection, but not the severity or symptomatic quality of infection, after WNV exposure in man.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 236 239 236 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Smithburn1">[1]</xref>
###xml 466 469 466 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Asnis1">[2]</xref>
###xml 470 473 470 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Hubalek1">[3]</xref>
###xml 474 477 474 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Lanciotti1">[4]</xref>
###xml 0 15 <span type="species:ncbi:11082">West Nile virus</span>
###xml 17 20 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 105 111 <span type="species:ncbi:9606">Humans</span>
###xml 222 227 <span type="species:ncbi:9606">woman</span>
###xml 241 244 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 396 403 <span type="species:ncbi:9606">patient</span>
###xml 710 713 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 816 819 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 854 859 <span type="species:ncbi:9606">human</span>
###xml 942 948 <span type="species:ncbi:9796">horses</span>
West Nile virus (WNV) is a re-emerging flavivirus transmitted by mosquitoes to several species of birds. Humans and several other mammalian species may be accidental dead-end hosts. First isolated in Uganda from a febrile woman in 1937 [1], WNV has caused sporadic outbreaks in the Middle East, Africa, Western Asia, Europe, and Australia. In the Western Hemisphere, it was first isolated from a patient during an outbreak of meningoencephalitis in New York in 1999 [2],[3],[4]. Since then it has rapidly spread across the United States into Canada and Central and South America, and has caused annual outbreaks of disease. Through November 18, 2008, there have been 28,906 US laboratory-confirmed symptomatic WNV-seropositive cases reported to the Centers for Disease Control and Prevention (CDC), with 1121 (3.9%) WNV-induced deaths (). In addition to human infections, the virus has caused significant morbidity and mortality in birds and horses.
###end p 6
###begin p 7
###xml 148 151 136 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mostashari1">[5]</xref>
###xml 310 313 298 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Hayes1">[6]</xref>
###xml 211 214 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 399 404 <span type="species:ncbi:9606">human</span>
###xml 405 408 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
In the US, seroprevalence is approximately3% in the general population and 20-30% of infected individuals have been estimated to become symptomatic [5]. Clinical manifestations include West Nile fever (WNF) and WNV-induced neuroinvasive disease (WNND), which manifests primarily as meningitis and encephalitis [6]. To date, no specific antiviral agents or vaccines have been approved by the FDA for human WNV infection, and treatment is supportive. Survivors of WNND may develop long-term neurologic sequelae.
###end p 7
###begin p 8
###xml 535 538 535 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Samuel1">[7]</xref>
###xml 723 726 723 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Hovanessian1">[8]</xref>
###xml 20 23 <span type="species:ncbi:9606">man</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 321 324 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Viral infections in man are typically controlled in part by early induction of type I interferon (IFN), which initiates a cascade of innate mechanisms that impair virtually all aspects of the viral life cycle. Genetic studies in mice have identified several type I IFN-regulated anti-viral effector pathways that control WNV replication, including the double-stranded RNA-dependent protein kinase (PKR) mechanism of protein synthesis inhibition, and the 2'-5' oligoadenylate synthetase (OAS) pathway of RNaseL-mediated RNA degradation [7]. OAS enzymes catalyze the synthesis of 2'-5'-linked oligoadenylates (2-5A) from ATP, which can then bind and activate latent RNaseL resulting in the degradation of host and viral RNAs [8].
###end p 8
###begin p 9
###xml 143 146 143 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Samuel1">[7]</xref>
###xml 147 150 147 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Samuel2">[9]</xref>
###xml 225 228 225 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flv</italic>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Sangster1">[10]</xref>
###xml 329 333 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Sangster2">[11]</xref>
###xml 335 338 335 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flv</italic>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mashimo1">[12]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Perelygin1">[13]</xref>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 647 651 647 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1</italic>
###xml 684 688 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mashimo2">[14]</xref>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Scherbik1">[15]</xref>
###xml 820 825 820 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 863 867 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Rogozin1">[16]</xref>
###xml 908 913 908 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 965 973 965 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1045 1050 1045 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 1113 1117 1113 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-KajasteRudnitski1">[17]</xref>
###xml 1118 1122 1118 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Lucas1">[18]</xref>
###xml 1171 1176 1171 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 1283 1287 1283 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Scherbik2">[19]</xref>
###xml 1383 1390 1383 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1395 1403 1395 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1438 1443 1438 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 129 132 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 213 218 <span type="species:ncbi:10090">mouse</span>
###xml 297 300 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 671 676 <span type="species:ncbi:10090">mouse</span>
###xml 936 939 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 999 1002 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1203 1208 <span type="species:ncbi:10090">mouse</span>
###xml 1289 1292 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1347 1352 <span type="species:ncbi:10090">mouse</span>
###xml 1496 1501 <span type="species:ncbi:10090">mouse</span>
Targeted gene disruption in mice has revealed a critical role for the type I IFN Receptor, PKR and RNaseL for survival following WNV infection [7],[9]. A critical role for OAS emerged from genetic analysis of the mouse locus flv, which determines in an autosomal dominant manner susceptibility to WNV and other flaviviruses [10],[11]. Flv has recently been mapped by two groups working independently [12],[13] to a missense mutation in the 2'-5' oligoadenylate synthetase 1b (oas1b) gene, which results in a truncated protein. How this mutation actually works has not yet been fully delineated. It clearly is not redundant with the multiple other oas1 genes found in the mouse genome [14]. However, there is evidence that protection may not actually be mediated through RNase L [15], and it is not yet known whether the oas1b gene product is enzymatically active [16]. The genetic data suggesting a role for oas1b in protection against WNV in mice are supported by in vitro experiments showing that WNV replication in cells expressing wild-type oas1b is less efficient than in cells expressing the truncated form [17],[18]. Furthermore, genetic knock-in of the resistant oas1b allele into a susceptible mouse strain resulted in resistance to Yellow Fever Virus, a related flavivirus [19]. WNV susceptibility has not been reported in this knock-in mouse. Taken together, the combined in vivo and in vitro data suggest an important role of oas1b in innate resistance to flavivirus infection in the mouse.
###end p 9
###begin p 10
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mashimo2">[14]</xref>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 338 349 338 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
###xml 349 353 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Glass1">[20]</xref>
###xml 354 358 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Lim1">[21]</xref>
###xml 410 421 406 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
###xml 717 721 697 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 727 731 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Yakub1">[22]</xref>
###xml 824 832 804 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS-Like</italic>
###xml 834 838 814 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 856 860 836 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 962 965 942 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Hovanessian1">[8]</xref>
###xml 1012 1016 992 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 1103 1107 1083 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 1242 1249 1222 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 110 116 <span type="species:ncbi:9606">humans</span>
###xml 128 131 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 162 167 <span type="species:ncbi:9606">human</span>
###xml 168 171 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 261 266 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 469 472 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 582 585 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 696 699 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1034 1037 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1131 1134 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1201 1204 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1220 1225 <span type="species:ncbi:9606">human</span>
Thus, we hypothesized that polymorphisms in the human ortholog of oas1b, OAS1[14], could influence outcome in humans exposed to WNV. Established risk factors for human WNV disease include age, immunosuppression, and genetic deficiency in the chemokine receptor/HIV-1 coreceptor CCR5, due to homozygous inheritance of the defective allele CCR5Delta32[20],[21]. Despite the strong epidemiologic association with CCR5Delta32, only approximately4% of Caucasian symptomatic WNV-infected individuals can be accounted for by CCR5 deficiency, indicating that other genetic risk factors for WNV disease may exist. A small case-control study (n = 27 cases) failed to find evidence of association of severe WNV disease with two OAS1 SNPs [22]. Instead, the investigators found a strong association with a silent variant (rs3213545) in OAS-Like (OASL), a paralogue of OAS1 located approximately 8 megabases away that has not been found to encode a protein with OAS activity [8]. In this report, we attempted to validate the OASL association with WNV, but could not. Instead, we found a consistent association of an OAS1 SNP and infection with WNV from samples collected from five independent US centers, and with WNV replication in human lymphoid tissue ex vivo.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
Structure and function of OAS1 SNP rs10774671
###end title 12
###begin p 13
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1</italic>
###xml 238 245 238 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1a-h</italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mashimo2">[14]</xref>
###xml 371 375 371 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mashimo2">[14]</xref>
###xml 550 554 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 589 593 589 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 684 688 684 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 718 721 718 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS</italic>
###xml 739 743 739 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 745 749 745 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS3</italic>
###xml 754 758 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS2</italic>
###xml 776 780 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Justesen1">[24]</xref>
###xml 794 802 794 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g001">Figure 1</xref>
###xml 832 836 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 1436 1444 1436 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g001">Figure 1</xref>
###xml 1678 1682 1678 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 1842 1846 1842 1846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 2296 2300 2296 2300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 2479 2483 2479 2483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 2484 2488 2484 2488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Justesen1">[24]</xref>
###xml 71 74 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 87 90 <span type="species:ncbi:9606">man</span>
###xml 179 184 <span type="species:ncbi:10090">mouse</span>
###xml 286 291 <span type="species:ncbi:9606">human</span>
###xml 678 683 <span type="species:ncbi:9606">Human</span>
###xml 2591 2596 <span type="species:ncbi:9606">human</span>
###xml 2597 2600 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
To investigate the role of the OAS system in controlling outcome after WNV exposure in man, we scanned the OAS1 gene for known polymorphisms that occur in this region. Unlike the mouse genome, where 8 copies of oas1 have been identified (oas1a-h), there is only one copy of OAS1 in the human genome, although alternative splicing gives rise to several isoforms [14]. All OAS1 splice variants include exons 1-5, but vary with regard to downstream exons, and thus produce proteins of various sizes, including the p42, p44, p46, p48, and p52 forms [14],[23]. We identified common SNPs in the OAS1 gene region in the CEPH cohort using data from the International HapMap Project (). Human OAS1 is one of three genes in the OAS cluster, ordered OAS1, OAS3 and OAS2 on chromosome 12 [24]. As shown in Figure 1, at least eleven SNPs in the OAS1 region have been found to cluster into two blocks of linkage disequilibrium (LD). The first block contains four SNPs, three of which are found within the first intron (rs7956880, rs10744785, and rs4766662) and one of which (rs2158390) is found in the 5'UTR. The second block contains seven SNPs, with rs3741981 in exon 3; rs2057778, rs2285934 and rs2285934 in intron 3; rs10774671 located at the last nucleotide in intron 5; rs1051042 and rs2660 in exon 7; and rs7135577 in the 3'UTR. The SNPs found in block 1 are not in coding regions. The six SNPs in block 2 excluding rs3741981 are in tight LD (Figure 1, the black region in block 2) and form two haplotypes that have been previously shown by Bonnevie-Nielsen and colleagues to be highly associated with the level of OAS enzymatic activity measured in peripheral blood mononuclear cells [23]. These investigators concluded that rs10774671 is most likely to be the functional SNP in this block because it sits at the last nucleotide of intron 5 in the OAS1 gene and serves as a splice acceptor site for exon 7. The G allele is predicted to allow splicing to occur resulting in the production of a p46 form with high enzymatic OAS activity. The A allele is predicted to prevent splicing at this site; instead, splicing occurs further downstream, resulting in two other forms, designated p48 and p52 associated with lower OAS enzymatic activity. Heterozygotes were reported to have intermediate OAS activity [23]. Although other splice variants of this gene exist, including p42 and p44, the splice variants that arise from the use of exon 7 (p46, p48, and p52) are controlled by rs10774671 [23],[24]. Thus, this polymorphism is a biologically plausible genetic probe to investigate the role of OAS1 in human WNV disease.
###end p 13
###begin title 14
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 33 38 <span type="species:ncbi:9606">human</span>
Haplotype block structure of the human OAS1 gene in the CEPH cohort.
###end title 14
###begin p 15
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 253 254 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
The location of rs10774671 (boxed) and the surrounding SNPs in and around the OAS1 gene are shown. LD block structure of the OAS1 gene found in the CEPH cohort was analyzed using Haploview version 4.0. Pairwise r2 values are scaled in gray with higher r2 values shown in darker color; black indicates an r2 = 1.
###end p 15
###begin title 16
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants and genotype analysis of OAS1 SNP rs10774671
###end title 16
###begin p 17
###xml 389 396 389 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000321-t001">Table 1</xref>
###xml 1021 1025 1021 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Orton1">[25]</xref>
###xml 1026 1030 1026 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Stramer1">[26]</xref>
###xml 44 47 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 133 136 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 186 189 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 203 210 <span type="species:ncbi:9606">patient</span>
###xml 473 476 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 663 666 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 799 802 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
To test whether this SNP is associated with WNV infection, we obtained serum or plasma from five independent US sources of Caucasian WNV+ individuals (n = 501). We collected symptomatic WNV-seropositive patient samples (n = 331) from the following state public health departments and outbreak years: Arizona (2004), California (2005), Colorado, (2003) and Illinois (2005-6) as detailed in Table 1. These samples were from individuals who sought medical attention and where WNV was considered in the differential diagnosis because of compatible signs and symptoms (fever, meningitis, encephalitis) and confirmed by serologic testing. We also obtained asymptomatic WNV-seropositive blood donor samples (n = 170) from the American Red Cross (ARC) national blood supply screening program, identified as WNV nucleic acid amplification test (NAT) reactive and confirmed by serologic testing. These individuals remained symptom-free, according to self-assessment in a follow-up questionnaire, for at least 2 weeks post-donation [25],[26].
###end p 17
###begin title 18
Characteristics and genotypes of self-reporting Caucasian study subjects.
###end title 18
###begin p 19
Cases from US states were classified into either West Nile fever (WNF), West Nile neuroinvasive disease (WNND), or unspecified disease categories by physician interview. All samples from ARC experienced no symptoms as assessed by questionnaire >/=2 weeks post-donation.
###end p 19
###begin p 20
###xml 192 195 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 198 201 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 228 231 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 234 237 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Mortality data do not include Illinois for which clinical outcome was not provided. RBD, random blood donors; AZ, Arizona; CO, Colorado; CA, California; IL, Illinois; ARC, American Red Cross; WNV+, WNV-seropositive individuals; WNV-, WNV-seronegative controls. All groups were in Hardy-Weinberg equilibrium. Genotypic frequencies where the total does not equal 100.0% are due to rounding imprecision.
###end p 20
###begin p 21
###xml 195 198 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 353 356 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 396 399 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 437 440 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
For comparison, we obtained two groups of US Caucasian control samples (n = 552). The first was comprised of healthy US Caucasian random blood donors (RBD) collected prior to the introduction of WNV into the US in 1999 (n = 360). The second consisted of healthy US blood donors collected by the ARC who were identified during routine blood screening as WNV false positives (initial reactivity by WNV NAT that could not be replicated and WNV-seronegative (n = 192)).
###end p 21
###begin p 22
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 414 415 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 427 428 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 544 551 544 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000321-t001">Table 1</xref>
###xml 727 731 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Fedetz1">[27]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Field1">[28]</xref>
###xml 737 741 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Smyth1">[29]</xref>
###xml 229 236 <span type="species:ncbi:9606">patient</span>
###xml 335 338 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
We limited the analysis to self-reporting Caucasian individuals because the allele frequency of the OAS1 rs10774671 SNP varies according to race (). In both cases and controls, the overall genotyping success rate was >96.0%. 156 patient samples were re-tested using a second genotyping method with 100% concordance. Within each group (WNV+ and control), the OAS1 genotypes were in Hardy-Weinberg equilibrium (HWE; p = 0.51 and p = 0.93, respectively). In our control samples (n = 552), the frequency of the OAS1 rs10774671 AA genotype shown in Table 1 (38.0%) was consistent with the observed AA genotypic frequency in other published Caucasian cohorts representing over 5000 individuals predominantly from Europe (36.8-41.1%) [27],[28],[29] as well as the published report in the CEPH cohort in the HapMap Project (39%, n = 59; ).
###end p 22
###begin title 23
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 43 46 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
OAS1 rs10774671 AA genotype is elevated in WNV-infected individuals
###end title 23
###begin p 24
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 258 265 258 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000321-t002">Table 2</xref>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 527 528 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 539 546 539 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000321-t002">Table 2</xref>
###xml 796 797 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 808 815 808 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000321-t002">Table 2</xref>
###xml 1188 1197 1188 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g002">Figure 2A</xref>
###xml 1738 1753 1738 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pan troglodytes</italic>
###xml 1784 1793 1784 1793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g002">Figure 2B</xref>
###xml 1922 1923 1922 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2168 2169 2168 2169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2284 2288 2284 2288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 113 116 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 426 429 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 884 887 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1128 1131 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1245 1248 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1738 1753 <span type="species:ncbi:9598">Pan troglodytes</span>
###xml 1826 1829 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 2363 2366 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
A genotypic contingency analysis (3x2) for OAS1 rs10774671 revealed a statistically significant association when WNV-positive samples were compared to controls (p = 0.0008). In our analysis, we considered the dominant, recessive and additive genetic models (Table 2), and all were statistically significant (p<0.05). Using the recessive model when all cases were grouped together, the AA genotype was significantly greater in WNV-positive subjects than in controls (Odds Ratio (OR) = 1.6 [95% Confidence Interval (CI) 1.3-2.1, p = 0.0001; Table 2). A similar trend in OR was observed in each of the 5 centers when considered separately, ranging between 1.5 and 1.7. Analysis of the data using the additive model also showed a highly significant association (OR = 1.4 per allele [95% CI 1.2-1.7], p = 0.0003; Table 2) indicating that having more A alleles was significantly greater in WNV-positive individuals than in controls. The OR for each center when considered separately was less consistent in this model, spanning between 1.2 and 2.0. To determine which model fits the data best, we analyzed the predicted probability of WNV infection by copies of A allele under the three models (Figure 2A). Superimposed are the observed proportions of WNV-positive individuals by copies of A (square boxes) along with the 95% CI. By comparing the observed to predicted proportion of cases by number of alleles using chi-square goodness-of-fit tests, we determined that the recessive and additive models are approximately equally supported by the data, with the dominant model having a decidedly poorer fit. We also analyzed each genotype separately, using GG as the reference genotype, since the G allele is the ancestral allele (from published Pan troglodytes sequence data, ). As shown in Figure 2B, the strongest association with WNV infection was observed when AA was compared to the GG genotype (OR = 1.8, 95% [CI] 1.2-2.7, p = 0.002). There was also a statistically significant increase between the AG and AA genotypes (OR = 1.5 95% [CI] 1.2-2.0, p = 0.002). The comparison between the GG and AG genotypes was not statistically significant (OR = 1.2, 95% [CI] 0.8-1.7, p = 0.38), suggesting a better fit for the recessive model. Taken together, these data show that the AA genotype of OAS1 at SNP 10774671 is significantly elevated in individuals seropositive for WNV.
###end p 24
###begin title 25
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 37 40 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
OAS1 allele dosage effect on risk of WNV infection.
###end title 25
###begin p 26
###xml 657 658 657 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 51 54 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 325 328 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
(A) A plot of the estimated probabilities of being WNV-positive as a function of the number of copies of rs10774671 A allele under three different genetic models. The solid line is the additive model; the dotted line is the recessive model; the dashed line is the dominant model. Also graphed are the observed proportions of WNV cases (solid squares) along with 95% CI (solid vertical lines). (B) The allele dosage effect of the A allele for SNP rs10774671 was examined using GG homozygous individuals as a reference genotype. OR (bars) were calculated, and 95% CI shown (lines) were determined for all study subjects. Chi-square test was used to calculate P values (shown).
###end p 26
###begin title 27
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 53 56 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
OAS1 rs10774671 is associated with increased risk of WNV infection.
###end title 27
###begin p 28
###xml 169 172 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
OR, odds ratio; CI, confidence interval; ARC, American Red Cross. Values were calculated in comparison to the genotype frequency in 552 healthy North American Caucasian WNV-seronegative control samples. Genetic models assume the ancestral G allele as the reference allele. Recessive, GG and GA genotypes combined; Dominant, GA and AA genotypes combined; Additive, GG versus AG and AG versus AA. ORs calculated using JMP software.
###end p 28
###begin p 29
p value calculated using Fisher's exact test.
###end p 29
###begin p 30
OR is infinite.
###end p 30
###begin title 31
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
OAS1 rs10774671 AA genotype is associated with infection and not severity of clinical outcome
###end title 31
###begin p 32
###xml 444 453 444 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g003">Figure 3A</xref>
###xml 585 589 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 645 652 645 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000321-t003">Table 3</xref>
###xml 657 666 657 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g003">Figure 3A</xref>
###xml 912 916 912 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 64 67 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 190 193 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 300 303 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 480 487 <span type="species:ncbi:9606">patient</span>
###xml 841 844 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 987 990 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
We next asked whether the elevated frequency of the A allele in WNV-seropositive subjects varied according to clinical outcome. The AA genotypic frequency for the four groups of symptomatic WNV+ subjects ranged between 47.1-51.1% (average 49.5%, n = 331). The AA genotypic frequency for asymptomatic WNV+ subjects from the ARC fell within this range at 48.8% (n = 170). In contrast, the AA frequency in the control samples was 38.0% (n = 552) (Figure 3A). Analysis of symptomatic patient samples for whom clinical outcome data were available (n = 294) showed a similar distribution of OAS1 genotypes in both the WNF and WNND clinical subgroups (Table 3 and Figure 3A). With regard to death as an outcome, the sample size is underpowered for analysis: only 13 of all 294 cases for which clinical outcome data were available experienced fatal WNV infection. These data are most consistent with the hypothesis that OAS1 at SNP 10774671 is a risk factor for seroconversion after exposure to WNV, but not for specific clinical manifestations.
###end p 32
###begin title 33
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 87 90 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
OAS1 rs10774671 AA genotype frequency is elevated in both symptomatic and asymptomatic WNV-seropositive subjects.
###end title 33
###begin p 34
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 64 67 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 96 99 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 189 192 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 286 289 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
(A) A plot of the OAS1 rs10774671 AA genotypic frequency in all WNV-positive samples (n = 501), WNV-positive samples from individuals who remained symptom-free (asymptomatic; n = 170), and WNV-positive samples from individuals who experienced symptomatic disease (n = 331). Symptomatic WNV-seropositive cases were further examined based on the CDC-defined clinical definition of WNF (n = 119) or WNND (n = 164). Black bar and the dotted line indicate the genotypic frequency of the control population (n = 552). (B) A similar analysis was performed for the OASL rs3213545 TT genotype.
###end p 34
###begin title 35
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 38 46 38 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS-Like</italic>
###xml 118 121 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
Distribution of OAS1 (rs10774671) and OAS-Like (rs3213545) genotypes as a function of clinical outcome in symptomatic WNV-seropositive patients.
###end title 35
###begin p 36
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients were classified into either West Nile fever (WNF), West Nile neuroinvasive disease (WNND), or unspecified disease categories by physician interview. Data do not include the Illinois cases for which no clinical outcome information was provided. No statistically significant differences were observed comparing the genotype frequencies of WNF versus WNND. With regard to death as an outcome, the sample size is underpowered for analysis.
###end p 36
###begin title 37
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 38 49 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
OAS1 SNP rs10774671 is independent of CCR5Delta32 and age
###end title 37
###begin p 38
###xml 32 43 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
###xml 109 113 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Glass1">[20]</xref>
###xml 114 118 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Lim1">[21]</xref>
###xml 162 166 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 217 228 213 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
###xml 262 266 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 343 350 335 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5+/+</italic>
###xml 362 375 354 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5+/&#916;32</italic>
###xml 404 423 392 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32/&#916;32</italic>
###xml 497 501 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 544 555 524 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
###xml 635 639 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Glass1">[20]</xref>
###xml 640 644 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Lim1">[21]</xref>
###xml 666 670 642 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 694 698 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 766 774 742 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000321.s001">Table S1</xref>
###xml 779 780 753 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 788 789 762 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 97 100 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 185 188 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 270 273 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
We previously demonstrated that CCR5Delta32 homozygosity is a strong risk factor for symptomatic WNV disease [20],[21]. To investigate whether the association of OAS1 SNP 10774671 with WNV infection is independent of CCR5Delta32, we analyzed the distribution of OAS1 in WNV+ subjects from the four groups of symptomatic US Caucasians who were CCR5+/+ (n = 261), CCR5+/Delta32 heterozygotes (n = 53), and CCR5Delta32/Delta32 homozygotes (n = 17). The expected frequencies were calculated solely on OAS1 HWE considerations, since the increase in CCR5Delta32 homozygotes resulted in skewing of HWE for this allele, as previously reported [20],[21]. The distribution of OAS1 genotypes according to CCR5 genotype did not differ significantly from expectation as shown in Table S1 (chi2 = 5.2, p = 0.26) suggesting that these alleles assort independently.
###end p 38
###begin p 39
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 270 278 270 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000321.s002">Table S2</xref>
###xml 58 61 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 134 137 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Since age is also an accepted risk factor for symptomatic WNV infection, we determined OAS1 SNP 10774671 genotypes in all symptomatic WNV+ subjects stratified by age; <45 years old (n = 99), between 45 and 64 years old (n = 131), and >64 years old (n = 101) as shown in Table S2, but found no significant differences.
###end p 39
###begin title 40
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 56 59 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Lack of OASL SNP rs3213545 association with symptomatic WNV disease
###end title 40
###begin p 41
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Yakub1">[22]</xref>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 558 566 558 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000321.s003">Table S3</xref>
###xml 683 691 683 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000321.s003">Table S3</xref>
###xml 760 769 760 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g003">Figure 3B</xref>
###xml 1023 1030 1023 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000321-t003">Table 3</xref>
###xml 1035 1044 1035 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g003">Figure 3B</xref>
###xml 115 118 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 225 228 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 287 290 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 543 546 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 832 840 <span type="species:ncbi:9606">patients</span>
###xml 933 936 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
We next attempted to validate the association previously identified by Yakub et al. between OASL SNP rs3213545 and WNV infection [22]. Contingency analysis (3x2) did not reveal any significant association (p = 0.93) when the WNV-infected seropositive subjects (n = 501) were compared to WNV-seronegative controls (n = 552). Analysis of the additive model (OR = 1.0 [95%CI 0.8-1.3], p = 0.94), the recessive model (OR = 1.0, [95%CI 0.69-1.6], p = 0.83), and the dominant model (OR = 1.0, [95%CI 0.8-1.3], p = 0.82) revealed no association with WNV infection (Table S3). When samples collected from each of the 5 centers were analyzed separately, no significant association was found (Table S3). The frequency of TT homozygosity was not elevated above controls (Figure 3B) and did not vary between asymptomatic donors and symptomatic patients. Since the previous study by Yakub et al. showed an association between this SNP and severe WNV disease, we also looked for an association according to clinical outcome. As shown in Table 3 and Figure 3B, no association was found with either WNF or WNND, the more severe CDC clinical definition.
###end p 41
###begin title 42
###xml 36 39 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 55 60 <span type="species:ncbi:9606">human</span>
Development of an ex vivo model for WNV replication in human lymphoid tissue
###end title 42
###begin p 43
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 250 257 250 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Bourne1">[30]</xref>
###xml 411 419 411 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Pierson1">[31]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Rios1">[32]</xref>
###xml 1069 1078 1069 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g004">Figure 4A</xref>
###xml 1312 1321 1312 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g004">Figure 4B</xref>
###xml 50 53 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 128 131 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 399 404 <span type="species:ncbi:9606">human</span>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
###xml 728 731 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1239 1242 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1358 1361 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1572 1575 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1636 1639 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
To directly assess the role of OAS1 during active WNV replication in human cells, we developed an experimental ex vivo model of WNV infection using explants of human tonsil tissue. This model may mimic the early events after infection that may occur in vivo in the draining lymph node, shown in mice to be an early site of viral replication that precedes CNS spread [30]. Since infection in primary human cells in vitro typically requires exogenous stimulation or activation [31],[32], this system is more natural in that the architecture and composition of the primary lymphoid tissue are preserved and no exogenous stimuli are added. Explanted tissue from patients undergoing tonsillectomies was sectioned and inoculated with WNV. For each experimental condition, 27 blocks of tissue were sectioned per donor to control for variation in the number of susceptible cells that may occur between individual slices of tissue from the same donor. Supernatant from the cultured tissue was tested every third day for virus using a focus forming unit (FFU) assay. As shown in Figure 4A, virus was detected in the culture supernatant at the earliest time point (day 3) and increased throughout the 12 day culture for each of the 21 donors tested. WNV-infected cells were visible by direct immunostaining of the tissues (Figure 4B). Tonsils from all donors supported WNV replication to high levels that varied widely among donors, particularly at early time points post-infection (e.g. greater than 4 logs variability at day 3). This model may be useful not only for investigating WNV pathogenesis but also for testing the efficacy of potential WNV therapeutics.
###end p 43
###begin title 44
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ex vivo</italic>
###xml 17 20 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 45 50 <span type="species:ncbi:9606">human</span>
Ex vivo model of WNV replication in cultured human lymphoid tissue.
###end title 44
###begin p 45
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 648 655 648 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 63 66 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 93 96 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 533 536 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 555 558 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
(A) Blocks of human tonsil tissue were inoculated ex vivo with WNV. Culture supernatant from WNV-infected and -uninfected tonsil tissue was sampled every third day for 12 days and viral titers assessed by FFU assay. 27 tissue blocks were used per experimental condition for each donor. The calculated maximal viral titer based on inoculum alone on day 0 is 1500 FFU/ml. Data represent the mean value of duplicate measurements with standard deviation. Note that data were not assessed for three patients on day 12. (B) Representative WNV immunostaining of WNV-infected (left panel) or donor-matched uninfected lymphoid tissue (right panel) cultured ex vivo for nine days. Scale bar, 100 microm.
###end p 45
###begin title 46
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 6 9 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Early WNV replication may be regulated by OAS1 genotype
###end title 46
###begin p 47
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 419 428 419 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g005">Figure 5A</xref>
###xml 709 710 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 719 728 707 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g005">Figure 5A</xref>
###xml 797 798 773 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 820 821 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 902 910 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN&#946;1</italic>
###xml 988 989 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1011 1012 984 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1038 1047 1011 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g005">Figure 5B</xref>
###xml 1188 1192 1161 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 1372 1381 1345 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g005">Figure 5C</xref>
###xml 1396 1405 1369 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g005">Figure 5D</xref>
###xml 1413 1417 1386 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 1556 1560 1529 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 1658 1667 1631 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g005">Figure 5E</xref>
###xml 2019 2023 1980 1984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 2215 2219 2176 2180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 263 266 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 366 369 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 626 629 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1830 1833 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 2114 2117 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 2131 2136 <span type="species:ncbi:9606">human</span>
The variation in virus production we observed among donors provided an ideal opportunity to test the dependence of viral replication on OAS1 genotype in intact human tissue, assuming that OAS1 mRNA was expressed in the tissue. Twelve of the 21 tissues tested for WNV replication were available for RNA extraction to investigate this. First we examined the effect of WNV infection on expression of all OAS1 transcripts (Figure 5A), using primers located between exons 2 and 3. OAS1 mRNA was detected in uninfected tissue from all 12 donors (data not shown), and expression of total OAS1 mRNA was induced approximately2 fold by WNV compared with donor-matched uninfected control tissue at day 3 post-infection (p = 0.01; Figure 5A). This increased to approximately4.6 fold induction for both day 6 (p = 0.002) and day 12 (p<0.0001) after infection. Since OAS1 is an IFN-stimulated gene, we also measured IFNbeta1 in these samples and observed a significant increase above control at day 6 (p = 0.002) and day 12 (p = 0.007) post infection (Figure 5B). These 12 samples were also tested by RT-PCR for OAS1 rs10774671 A and G allele-specific transcripts using a previously established method [23]. Both A and G allele-specific transcripts (319 and 417 bp amplicons for A allele; 416 bp amplicon for G allele) were detected in appropriate uninfected tissue from all 12 donors (Figure 5C). As shown in Figure 5D, total OAS1 SNP rs10774671-specific mRNA modestly increased in a time-dependent manner after infection. This was due at least in part to induction of OAS1 SNP rs10774671 A allele-specific RNA, as shown by analysis of tissue from AA homozygotes (n = 5; Figure 5E). Since RNA generated from the A and G alleles differ by only 1 nucleotide, we were unable to quantitate the relative induction of A and G allele-specific RNA in WNV-infected tissue from AG heterozygotes. We observed approximately1.5-fold induction of G allele-specific mRNA in infected tissue from the one GG homozygote that was available. Thus both OAS1 SNP rs10774671 variants of interest are present at the RNA level throughout the course of WNV infection of human tonsil tissue, allowing us to ask whether virus replication in this system is OAS1 genotype-dependent.
###end p 47
###begin title 48
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 61 64 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Induction of OAS1 RNA in human lymphoid tissue infected with WNV.
###end title 48
###begin p 49
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 45 54 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#946;1</italic>
###xml 227 231 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 290 294 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 312 316 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 479 483 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 582 586 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 1127 1131 1122 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 1223 1227 1218 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 1282 1286 1274 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 1421 1422 1413 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1433 1434 1425 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1443 1444 1435 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 72 75 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 773 780 <span type="species:ncbi:9606">Patient</span>
###xml 898 901 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Quantitative RT-PCR analysis of OAS1 (A) and IFN-beta1 (B) induction in WNV-infected tissue versus matched uninfected tissue taken at various times post-infection from 12 patients and presented as means+/-SEM. Primers used for OAS1 analysis are located in exon 2 and 3 and thus amplify all OAS1 transcripts. (C) OAS1 genotypes were determined for SNP rs10774671 using ABI SNP genotyping methods. cDNA from uninfected blocks of human tonsil tissue were tested for the presence of OAS1 SNP-dependent splice variants using primers specifically flanking the SNP as previously described [23]. PCR products were resolved on 2% agarose gel. The presence of the G allele produced an amplicon of 416 bp, while the presence of the A allele gave rise to a 319 bp and 417 bp fragment. Patient genotypes are denoted above the lane; M, molecular weight marker. (D) RNA was extracted at the indicated times after WNV infection of tonsil tissues from 12 donors; uninfected tissue RNA from the same donor served as a control at each time point. cDNA generated was used for PCR using the same primers as described above. Amplicons for the total OAS1 rs10774671-specific transcripts were quantified using densitometric analysis normalized to beta-actin. The mean+/-SEM are shown. (E) The induction of OAS1 rs10774671 A-allele specific RNA from AA homozygous donors was analyzed separately (n = 5). Fold induction is shown as mean+/-SEM. ***p<0.0001; **p<0.005; *p<0.05.
###end p 49
###begin p 50
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 600 608 600 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000321-g006">Figure 6</xref>
###xml 679 680 679 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 722 723 722 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 834 835 834 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 927 928 927 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 942 943 942 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 963 964 963 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1037 1038 1037 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1063 1064 1063 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1081 1082 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1158 1159 1158 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 39 42 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 100 107 <span type="species:ncbi:9606">patient</span>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
To test whether OAS1 variation affects WNV infection in human lymphoid tissue ex vivo, we genotyped patient samples for the OAS1 rs10774671 SNP. Of the 21 donors tested, 7 were homozygous for the A allele (33.3%), 2 were homozygous for the G allele (9.5%), and the remaining 12 were AG heterozygotes (57.2%). This distribution is similar to the genotypic distribution observed in controls. When viral production was analyzed as a function of OAS1 genotype, we found that tissues from individuals homozygous for the A allele supported higher levels than tissues from patients with AG or GG genotypes (Figure 6). The most significant difference was observed 3 days post infection (p<0.0001) with a mean viral titer of 3.9x104 ffu in tissues from donors with the AA genotype versus those from individuals who were either AG or GG (1.1x103 ffu). At day 6, the mean viral titer was still greater in AA than in non-AA tissues (1.7x106 versus 5.0x104 ffu, respectively; p = 0.002). At day 9, the differences in viral titer had decreased (1.3x106 ffu for AA versus 3.8x105 ffu for non-AA; p = 0.02). By day 12 post-infection, no significant difference was observed (p = 0.80). Thus the allele associated with higher OAS enzymatic activity (G) is associated with lower viral production for at least 75% of the period of observation after infection in lymphoid tissue.
###end p 50
###begin title 51
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 0 3 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 28 33 <span type="species:ncbi:9606">human</span>
WNV replication of cultured human lymphoid tissue ex vivo is OAS1 genotype-dependent.
###end title 51
###begin p 52
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
Viral titers measured at each three-day interval were plotted according to OAS1 splice acceptor site genotype. Data points represent the amount of virus measured at each three-day interval, and lines indicate the median value. Individuals homozygous for the A allele were compared to AG heterozygotes plus GG homozygotes. Note that viral titers for three patients were not assessed at day 12.
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 871 874 871 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flv</italic>
###xml 911 916 911 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 916 920 916 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mashimo1">[12]</xref>
###xml 921 925 921 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Perelygin1">[13]</xref>
###xml 949 953 949 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 953 957 953 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Mashimo2">[14]</xref>
###xml 1023 1027 1023 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 1450 1455 1450 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 129 132 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 145 151 <span type="species:ncbi:9606">humans</span>
###xml 318 321 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 369 376 <span type="species:ncbi:9606">patient</span>
###xml 463 466 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 516 524 <span type="species:ncbi:9606">patients</span>
###xml 693 696 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 741 746 <span type="species:ncbi:9606">human</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
###xml 943 948 <span type="species:ncbi:9606">human</span>
###xml 1032 1035 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1049 1052 <span type="species:ncbi:9606">man</span>
###xml 1356 1359 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1397 1403 <span type="species:ncbi:9606">humans</span>
###xml 1463 1468 <span type="species:ncbi:10090">mouse</span>
###xml 1515 1518 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1657 1684 <span type="species:ncbi:11072">Japanese encephalitis virus</span>
###xml 1710 1739 <span type="species:ncbi:11084">Tick-borne encephalitis virus</span>
The present study provides the first evidence in support of the hypothesis that OAS1 influences risk of infection in response to WNV exposure in humans. This is based on association of the OAS1 'A' allele at SNP rs10774671, which has previously been associated with low OAS enzymatic activity, with seropositivity for WNV using recessive and additive genetic models on patient samples collected from five US centers. We found that the AA genotype was elevated in WNV-positive individuals regardless of whether these patients remained asymptomatic or developed symptomatic disease, including WNF and WNND. We also observed that homozygosity for the A allele correlated with increased levels of WNV replication in primary lymphoid tissue from human donors. Moreover, the results are consistent with the previously reported identification of the flavivirus resistance locus flv in mice as a truncation mutation in oas1b[12],[13], the ortholog of human OAS1[14]. Our data do not confirm the previously published association of OASL and WNV infection in man. Together, these data suggest that OAS1 activity modulates early viral replication, and that decreased OAS1 activity is associated with increased risk of infection and seroconversion. These data suggest that carriers of the G allele, which is associated with high OAS1 activity, may effectively control WNV replication early after infection in humans through innate mechanisms. Furthermore, since oas1b in the mouse has been implicated in resistance not only to WNV, but to several other flaviviruses, this association may also be relevant for other medically important neurotropic flaviviruses, such as Japanese encephalitis virus, Yellow Fever virus, and Tick-borne encephalitis virus.
###end p 54
###begin p 55
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 188 191 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 359 362 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
There are several limitations to our study. First, like most gene association studies, the analysis is retrospective. Second, due to a limitation of sample availability the association of WNV infection with OAS1 SNP 10774671 was determined only in North American Caucasians. Third, the epidemiologic data, while consistent with a role for OAS1 in controlling WNV infection, do not establish causality versus linkage disequilibrium with an as yet unidentified causal variant. Importantly though, the variant tested has been previously associated with OAS function, and is therefore biologically plausible [23].
###end p 55
###begin p 56
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 671 675 671 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 793 797 793 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 850 854 850 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 896 901 896 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">oas1b</italic>
###xml 985 989 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Rogozin1">[16]</xref>
###xml 1040 1044 1040 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Scherbik1">[15]</xref>
###xml 117 120 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 275 278 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 508 511 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 627 632 <span type="species:ncbi:9606">human</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
Additional work will be needed to delineate the precise mechanisms by which OAS1 SNP rs10774671 variation may affect WNV infection. We were able to detect the OAS1 A and G allele transcripts in uninfected human tonsil tissue as predicted by donor genotype, and we found that WNV infection was able to induce total OAS1 RNA in the tissue as well as RNA specific for the OAS1 A and G alleles. However, additional work will be needed to determine OAS1 allele-specific activity in tonsil tissue as a function of WNV infection, and the relative contribution of each of the OAS1 isoforms present in the tissue. While OAS activity in human PBMCs has been reported to vary in an OAS1 SNP rs10774671-dependent manner, with the rank order GG>AG>AA, OAS enzymatic activity of purified protein encoded by OAS1 A and G allele variants has not yet been determined [23]. Furthermore, the mechanism of action of oas1b in mice is not yet clear, nor is there evidence that oas1b is enzymatically active [16] or that it functions through activation of RNaseL [15].
###end p 56
###begin p 57
###xml 776 780 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Fedetz1">[27]</xref>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Field1">[28]</xref>
###xml 786 790 786 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Smyth1">[29]</xref>
###xml 831 835 831 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Smyth1">[29]</xref>
###xml 1018 1022 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Fedetz1">[27]</xref>
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Field1">[28]</xref>
###xml 1832 1836 1832 1836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 1901 1902 1901 1902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 212 215 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 350 353 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 525 528 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Population stratification as a cause of skewed genotypic frequency is a concern in all gene association studies. Given the limited availability of genomic DNA from the small samples of serum available to us from WNV+ subjects, we were unable to address this issue directly. However, we believe this is unlikely to confound our results since the five WNV+ groups were from geographically distinct US populations yet had similar AA genotypic frequencies ranging from 47.1% to 51.4% with an average of 49.3%, whereas the two US WNV-negative control populations that we genotyped, which also were from distinct geographic regions, had much lower AA genotypic frequencies (36.7 and 40.6%) that both fell within a narrow range reported in previously published studies, (36.8-41.1%) [27],[28],[29]. In particular, Smyth et al reported an OAS1 SNP rs10774671 AA genotypic frequency of 41.1% for 4,735 subjects from the 1958 British Birth Cohort ()[29]; Fedetz et al reported a frequency of 36.8% for 424 Caucasians from Spain [27]; and the International HapMap Project reported a frequency of 39% in US Caucasians (n = 59; ). It is important to note that a fourth published study, by Field et al., reported an AA genotypic frequency of 49.9% [28]. This anomaly is most likely due to the use of a non-random population, namely the healthy siblings of diabetics. In particular, the A allele frequency in non-transmitted alleles of the parents, which would be expected to have nothing to do with disease, was 0.61 in this study, which would give an expected frequency of 0.61x0.61 = 37% for the AA genotype (L. Field, personal communication), compatible with the frequency found in all five other control populations. Of note, no difference in frequency was observed between cases and controls in a genetically unlinked but related variant in OASL (), where the odds ratio for all genetic models tested was 1.0, p>/=0.82.
###end p 57
###begin p 58
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Samuel2">[9]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Bourne1">[30]</xref>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Levy1">[33]</xref>
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-MunozJordan1">[34]</xref>
###xml 153 156 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 225 231 <span type="species:ncbi:9606">humans</span>
###xml 501 506 <span type="species:ncbi:9606">human</span>
###xml 537 540 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 774 777 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Animal studies have shown conclusively that the type I IFN system exerts potent antiviral effects critical for survival from viral infections, including WNV infection [9],[30],[33],[34]. However, there is limited evidence in humans supporting a role for endogenous type I IFN signaling at the level of viral pathogenesis. Our study suggests a potentially important role of this type I IFN-inducible pathway at the level of initial infection and containment of virus during the early phases of natural human infection. Our data show that WNV infection is less likely to result in seroconversion in individuals with the GG genotype (higher OAS enzymatic activity), suggesting that individuals with the AA genotype (lower enzymatic activity) are less likely to control initial WNV infection with innate immunity and initiate an adaptive immune response, signaled by seroconversion.
###end p 58
###begin p 59
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Field1">[28]</xref>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Smyth1">[29]</xref>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Hamano1">[35]</xref>
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-He1">[36]</xref>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Knapp1">[37]</xref>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 115 126 <span type="species:ncbi:11103">Hepatitis C</span>
###xml 242 253 <span type="species:ncbi:11103">Hepatitis C</span>
###xml 269 272 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 558 561 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Genetic variation in OAS1 has been previously associated with other diseases, including Type I Diabetes, SARS, and Hepatitis C. The associations in Type I Diabetes and SARS have been inconsistent in different studies [28],[29],[35],[36]. For Hepatitis C, a relative of WNV also in the flavivirus family, a polymorphism in the 3'-untranslated region of OAS1 has been associated with persistent infection [37]. This is particularly relevant since this polymorphism is in strong linkage disequilibrium with polymorphism rs10774671 which we have associated with WNV seroconversion [23].
###end p 59
###begin p 60
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 143 147 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Kim1">[38]</xref>
###xml 148 152 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Murashima1">[39]</xref>
###xml 439 443 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Kalil1">[40]</xref>
###xml 444 448 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Lewis1">[41]</xref>
###xml 449 453 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-ChanTack1">[42]</xref>
###xml 203 206 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 220 223 <span type="species:ncbi:9606">man</span>
###xml 292 295 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 539 542 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 626 629 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
A clinical implication of our results is that pharmacologic induction of OAS1, which has been shown to occur in response to IFNalpha treatment [38],[39] could be efficacious in the context of preventing WNV infection in man. While treatment with IFNalpha has been reported to be effective in WNV-infected patients, the world experience is limited to a small number of scattered case reports, and treatment failure has also been documented [40],[41],[42]. Our data support continued clinical research of IFNalpha as a therapeutic option in WNV disease. Finally, our data indicate that the great majority of risk of symptomatic WNV disease remains unexplained at the genetic level, and support continued research into variation in the type I IFN system as a factor contributing to the heterogeneity of outcome in this disease.
###end p 60
###begin title 61
Materials and Methods
###end title 61
###begin title 62
Study populations
###end title 62
###begin p 63
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Glass1">[20]</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Lim1">[21]</xref>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 850 854 850 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 1653 1657 1653 1657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Orton1">[25]</xref>
###xml 40 45 <span type="species:ncbi:9606">Human</span>
###xml 99 102 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 116 123 <span type="species:ncbi:9606">patient</span>
###xml 354 357 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 371 378 <span type="species:ncbi:9606">patient</span>
###xml 486 489 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 503 511 <span type="species:ncbi:9606">patients</span>
###xml 600 603 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 641 644 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 691 694 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
###xml 889 892 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1251 1254 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1314 1317 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1367 1370 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1476 1479 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 1508 1511 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
The study was approved by the Office of Human Subjects Research of the NIH. Samples of symptomatic WNV-seropositive patient cases from four US states (AZ, CO, CA, and IL) were collected as previously described [20],[21]. Since the allele frequency of this SNP varies by race (), and since information about race was not available for all subjects in the WNV-seropositive patient cases, we analyzed only self-reporting Caucasians (total n = 331 in the 4 US states combined). Symptomatic WNV-seropositive patients are defined as individuals who came to clinical attention with symptoms consistent with WNV disease (primarily WNF, WNND), where WNV was confirmed using serological tests. Of the WNV-seropositive samples received, sufficient DNA from self-reported Caucasian patients was available for analysis of 345 samples. Genotypes for both OAS1 and OASL were obtained for 331 symptomatic WNV-seropositive subjects with an overall genotyping success rate of 95.9%. Serum samples were collected from the following states and years: 1) Arizona from the 2004 epidemic (n = 135); 2) Colorado from the 2003 epidemic (n = 72); 3) California from the 2005 epidemic (n = 87); 4) Illinois from the 2005/2006 epidemic (n = 37). Plasma samples from asymptomatic WNV-seropositive blood donors from the American Red Cross (ARC WNV+) were collected between 2003-2008. Asymptomatic WNV-seropositive blood donors (n = 170) are defined as Caucasian random blood donors who tested reactive for WNV nucleic acid twice and were WNV IgM seropositive who remained asymptomatic for at least 2 weeks post donation as assessed by follow-up questionnaire as described previously [25].
###end p 63
###begin p 64
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Glass1">[20]</xref>
###xml 310 313 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 409 412 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 455 458 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 774 781 <span type="species:ncbi:9606">patient</span>
Two healthy US Caucasian control groups were established: 1) healthy unrelated US Caucasian random blood donors (RBD) from the NIH Department of Transfusion Medicine (n = 360) collected under an IRB-approved protocol [20]; and 2) healthy Caucasian blood donors from the American Red Cross (n = 192) who tested WNV nucleic acid reactive upon initial screen at the time of blood donation, but were negative for WNV nucleic acid upon retesting and were also WNV-seronegative for IgM (false positives). The following information was provided if available: age, gender, self-reported racial group, date of sample collection, and CDC-defined clinical presentation at the time of sample collection: WNF, WNND, and death. For all study samples, investigators were blinded to unique patient identifiers.
###end p 64
###begin title 65
DNA isolation and genotyping
###end title 65
###begin p 66
###xml 612 616 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Zimmerman1">[43]</xref>
###xml 821 825 803 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 865 869 847 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Fedetz1">[27]</xref>
200 microl of serum collected from Arizona, Colorado, California, and Illinois were thawed for genomic DNA purification using the QiaAmp 96 DNA Blood Kit according to the manufacturer's instructions (Qiagen, Valencia, CA). 250 microl of plasma collected from test subjects by the American Red Cross was purified using NucliSENS EasyMAG automated nucleic acid extraction technology (Biomerieux, Inc). Purified DNA was eluted into 100 microl of the recommended buffer and stored at 4degreesC until further use. DNA from NIH random blood donors was isolated from peripheral blood leukocytes as previously described [43]. SNPs were genotyped using the ABI 7900HT PCR System with TaqMan primer/probe mix predesigned and validated by ABI (C___2567433_10 and C__11753831_1_). PCR-RFLP was used as a second genotyping method for OAS1 SNP rs10774671 as previously described [27].
###end p 66
###begin title 67
Statistical analysis
###end title 67
###begin p 68
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 451 455 451 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 518 522 518 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 552 556 552 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OASL</italic>
###xml 1101 1103 1101 1103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 1245 1246 1245 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1391 1395 1391 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
Contingency tables were utilized to calculate genotypic and allelic frequency differences between cases and controls by comparing numbers of expected (Hardy-Weinberg equation) and observed individuals using chi-square tests of significance to obtain a two-sided p value using either 1 (2x2 table) or 2 (3x2 table) degrees of freedom. ORs were calculated using a recessive genetic model (i.e. AA verses AG plus GG for OAS1 and TT versus TC plus CC for OASL) or the dominant genetic model (i.e. AA plus AG versus GG for OAS1 and TT plus TC versus CC for OASL) by cross tabulation and 95% CI were estimated using the approximation of Woolf (GraphPad Software version 4.0b, San Diego, CA). The additive model OR values and 95% CI were calculated using JMP software. Chi-square was used unless otherwise indicated. ORs and CIs based on the additive model were estimated using JMP (SAS, version 7). Chi-square goodness-of-fit statistics were used to compare dominant, recessive, and additive models. The two-sided unpaired t-test was used to calculate statistical significance of viral replication after log10 transformation of the data for each time point and a two-sided paired t-test was used to calculate significance of gene expression analysis. P values were considered significant if <0.05 and the reported values have not been corrected for multiple comparisons. Linkage disequilibrium of OAS1 SNPs and resultant haplotypes were examined using Haploview 4.0 (available at ) using previously obtained data from the International HapMap project () on the CEU panel using release 21 data.
###end p 68
###begin title 69
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 13 18 <span type="species:ncbi:9606">human</span>
Infection of human lymphoid tissue ex vivo
###end title 69
###begin p 70
###xml 503 507 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Glushakova1">[44]</xref>
###xml 1038 1049 1032 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
###xml 1083 1087 1073 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-Glass1">[20]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 58 66 <span type="species:ncbi:9606">Children</span>
###xml 254 262 <span type="species:ncbi:9606">children</span>
###xml 613 616 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 673 676 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Human tonsils from routine tonsillectomy performed at the Children's Hospital National Medical Center in Washington, DC were collected under an Institutional Review Board-approved protocol from NICHD within a few hours after surgery. The mean age of the children used in this study was 5+/-3. Tonsils were dissected in blocks of approximately 2 mm. 9 tissue blocks per well in triplicate wells per condition were placed on top of collagen sponge gels floating in six-well plates as previously described [44]. All 27 tissue blocks from each donor were then individually inoculated with 5 microl containing 500 FFU WNV strain NY99, or left uninfected. We assessed productive WNV infection by measuring FFU as described above in culture medium pooled from 27 blocks during the previous 3 days between successive media changes. FFU at each time point represent the cumulative total of infectious virions produced. Coefficient of variation for each donor and each time point was calculated to be 13.3%. All tonsil donors were analyzed for the CCR5Delta32 mutation as previously described [20] and found to be wild type at this allele.
###end p 70
###begin title 71
Viral Titers
###end title 71
###begin p 72
###xml 894 895 850 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 896 897 852 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 465 468 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 614 619 <span type="species:ncbi:10090">mouse</span>
###xml 625 631 <span type="species:ncbi:9986">rabbit</span>
###xml 776 779 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Confluent Vero cells were grown in a 12 well plate in OptiPro SFM (Invitrogen) with 2% FBS (Hyclone) and 50 microg/ml gentamicin (ATCC). Supernatants from tonsil cultures were diluted and incubated on the cells for 1 hour at 37degreesC prior to overlaying with 2 ml Opti-MEM (Invitrogen) with 8 g/L methylcellulose (Sigma), 2% FBS and 50 microg/ml gentamicin. Plates were incubated for 2 days at 37degreesC, then washed 3 times with PBS. 500 microl of diluted anti-WNV anti-sera/well (HMAF, ATCC #VR-82) was incubated for 1 hour at 37degreesC. Plates were then washed 3 times and 500 microl of diluted (1:10) anti-mouse/anti-rabbit HRP labeled polymer (DAKO Cytomation) was added. Cells were incubated for 1 hour at 37degreesC, washed 3 times and focus forming units (FFU) of WNV were visualized by addition of 1 ml diaminobenzidine (DAB) mixture (4.5 mg DAB (Sigma) /10 ml PBS+4.5 microl 30% H202 /10 ml). Viral titers are expressed as FFU/ml.
###end p 72
###begin title 73
Real-time PCR
###end title 73
###begin p 74
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 290 295 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
RNA was extracted from lymphoid tissue using the RNeasy Tissue kit according to manufacturer's protocol (Qiagen). Reverse transcription was performed using Superscript III first strand synthesis Supermix (Invitrogen) with random hexamers. OAS1 (Hs00242943_m1), IFNbeta1 (Hs00277188_s1) and GAPDH (Hs00266705_g1) primer/probe sets were obtained from ABI and cycled on an ABI 7900HT PCR System. Each sample was normalized to GAPDH and fold change in infected samples were compared to uninfected donor-matched samples.
###end p 74
###begin title 75
Immunohistochemistry
###end title 75
###begin p 76
###xml 71 74 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
###xml 248 253 <span type="species:ncbi:9796">horse</span>
###xml 254 260 <span type="species:ncbi:3726">radish</span>
4-5 microm sections of paraffin-embedded slides were stained with anti-WNV hyperimmune mouse ascites fluid (HMAF, ATCC #VR-82) diluted 1:100 in antibody diluent, background reducing agent (DAKO Cytomation). After incubation with anti-mouse polymer-horse radish peroxidase (DAKO Cytomation), slides were developed with streptavidin and diaminobenzidine liquid (DAKO Cytomation) and counterstained with hematoxylin.
###end p 76
###begin title 77
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
Detection of OAS1 splice variants
###end title 77
###begin p 78
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000321-BonnevieNielsen1">[23]</xref>
###xml 266 288 266 288 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">F-ggcggaccctacaggaaact</named-content>
###xml 290 312 290 312 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">R-acaccagctcactgaggagc</named-content>
###xml 678 681 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
Tissues from 12 tonsil donor samples were tested for OAS1 SNP-specific mRNA. cDNA from uninfected and infected donor-matched samples for each time point amplified by PCR as previously described [23]. Briefly, primers were designed to flank the splice acceptor site (F-ggcggaccctacaggaaact; R-acaccagctcactgaggagc). The presence of a G allele resulted in a 416 bp amplicon, while the presence of the A allele resulted in 319 bp and 417 bp fragments. PCR products were resolved on a 2% agarose gel, visualized using ethidium bromide, and quantitated by densitometry normalized to beta-actin using Image J software version 1.38x. Fold change was calculated by comparing normalized WNV-infected measurements to normalized uninfected measurements for each time point for each donor.
###end p 78
###begin title 79
Supporting Information
###end title 79
###begin p 80
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 38 49 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5&#916;32</italic>
###xml 75 78 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Distribution of OAS1 (rs10774671) and CCR5Delta32 genotypes in symptomatic WNV-seropositive patients
###end p 80
###begin p 81
(0.03 MB DOC)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS1</italic>
###xml 86 89 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
###xml 103 110 <span type="species:ncbi:9606">patient</span>
Distribution of OAS1 (rs10774671) genotypes according to age in Caucasian symptomatic WNV-seropositive patient samples
###end p 83
###begin p 84
(0.03 MB DOC)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OAS-Like</italic>
###xml 60 63 <span type="species:ncbi:11082?0.9877551020408163">WNV</span>
OAS-Like SNP rs3213545 is associated with increases risk of WNV infection
###end p 86
###begin p 87
(0.04 MB DOC)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
###xml 515 523 <span type="species:ncbi:9606">Children</span>
###xml 593 598 <span type="species:ncbi:9606">human</span>
The authors thank Lawrence Faucette from NIAID for help with immunohistochemistry, Sudkamon Lekhong, Shuk Fong Yu, Ronald Cheshire, and William A. Frank from the Arizona Department of Health Services and Carol Glaser and Cynthia Jean from the California Department of Health Services, Viral and Rickettsial Disease Laboratory, for sample acquisition during the 2004 and 2005 epidemics, respectively. The authors would also like to thank Dr. D. Ashley Hill and the entire staff of the Department of Pathology of The Children's National Medical Center for their generous assistance in obtaining human tonsil tissues.
###end p 89
###begin title 90
References
###end title 90
###begin article-title 91
A neurotropic virus isolated from the blood of a native of Uganda.
###end article-title 91
###begin article-title 92
The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience.
###end article-title 92
###begin article-title 93
West Nile fever-a reemerging mosquito-borne viral disease in Europe.
###end article-title 93
###begin article-title 94
###xml 14 29 <span type="species:ncbi:11082">West Nile virus</span>
Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States.
###end article-title 94
###begin article-title 95
Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey.
###end article-title 95
###begin article-title 96
###xml 0 15 <span type="species:ncbi:11082">West Nile virus</span>
West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States.
###end article-title 96
###begin article-title 97
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons.
###end article-title 97
###begin article-title 98
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation.
###end article-title 98
###begin article-title 99
###xml 46 61 <span type="species:ncbi:11082">West Nile virus</span>
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival.
###end article-title 99
###begin article-title 100
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Genetic studies of flavivirus resistance in inbred strains derived from wild mice: evidence for a new resistance allele at the flavivirus resistance locus (Flv).
###end article-title 100
###begin article-title 101
###xml 64 69 <span type="species:ncbi:10090">mouse</span>
Mapping the Flv locus controlling resistance to flaviviruses on mouse chromosome 5.
###end article-title 101
###begin article-title 102
###xml 103 118 <span type="species:ncbi:11082">West Nile virus</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice.
###end article-title 102
###begin article-title 103
###xml 26 32 <span type="species:ncbi:10090">murine</span>
Positional cloning of the murine flavivirus resistance gene.
###end article-title 103
###begin article-title 104
###xml 99 105 <span type="species:ncbi:10090">murine</span>
Structural and functional genomics and evolutionary relationships in the cluster of genes encoding murine 2',5'-oligoadenylate synthetases.
###end article-title 104
###begin article-title 105
###xml 50 65 <span type="species:ncbi:11082">West Nile virus</span>
RNase L plays a role in the antiviral response to West Nile virus.
###end article-title 105
###begin article-title 106
Differential action of natural selection on the N and C-terminal domains of 2'-5' oligoadenylate synthetases and the potential nuclease function of the C-terminal domain.
###end article-title 106
###begin article-title 107
###xml 64 79 <span type="species:ncbi:11082">West Nile virus</span>
The 2',5'-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells.
###end article-title 107
###begin article-title 108
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
###xml 31 46 <span type="species:ncbi:11082">West Nile virus</span>
Infection of mouse neurones by West Nile virus is modulated by the interferon-inducible 2'-5' oligoadenylate synthetase 1b protein.
###end article-title 108
###begin article-title 109
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
Knock-in of the Oas1b(r) allele into a flavivirus-induced disease susceptible mouse generates the resistant phenotype.
###end article-title 109
###begin article-title 110
###xml 46 61 <span type="species:ncbi:11082">West Nile virus</span>
CCR5 deficiency increases risk of symptomatic West Nile virus infection.
###end article-title 110
###begin article-title 111
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: a meta-analysis of 4 cohorts in the US epidemic.
###end article-title 111
###begin article-title 112
###xml 118 133 <span type="species:ncbi:11082">West Nile virus</span>
Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection.
###end article-title 112
###begin article-title 113
Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene.
###end article-title 113
###begin article-title 114
Gene structure and function of the 2'-5'-oligoadenylate synthetase family.
###end article-title 114
###begin article-title 115
###xml 39 54 <span type="species:ncbi:11082">West Nile virus</span>
Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors.
###end article-title 115
###begin article-title 116
###xml 0 15 <span type="species:ncbi:11082">West Nile virus</span>
West Nile virus among blood donors in the United States, 2003 and 2004.
###end article-title 116
###begin article-title 117
OAS1 gene haplotype confers susceptibility to multiple sclerosis.
###end article-title 117
###begin article-title 118
OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes.
###end article-title 118
###begin article-title 119
No evidence for association of OAS1 with type 1 diabetes in unaffected siblings or type 1 diabetic cases.
###end article-title 119
###begin article-title 120
###xml 45 60 <span type="species:ncbi:11082">West Nile virus</span>
Early production of type i interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production.
###end article-title 120
###begin article-title 121
###xml 14 29 <span type="species:ncbi:11082">West Nile virus</span>
An infectious West Nile virus that expresses a GFP reporter gene.
###end article-title 121
###begin article-title 122
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 69 84 <span type="species:ncbi:11082">West Nile virus</span>
Monocytes-macrophages are a potential target in human infection with West Nile virus through blood transfusion.
###end article-title 122
###begin article-title 123
The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion.
###end article-title 123
###begin article-title 124
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses.
###end article-title 124
###begin article-title 125
Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population.
###end article-title 125
###begin article-title 126
Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study.
###end article-title 126
###begin article-title 127
###xml 61 78 <span type="species:ncbi:11103">hepatitis C virus</span>
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.
###end article-title 127
###begin article-title 128
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 154 165 <span type="species:ncbi:11103">hepatitis C</span>
2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
###end article-title 128
###begin article-title 129
###xml 82 93 <span type="species:ncbi:11103">hepatitis C</span>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients.
###end article-title 129
###begin article-title 130
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases.
###end article-title 130
###begin article-title 131
###xml 24 39 <span type="species:ncbi:11082">West Nile virus</span>
Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course.
###end article-title 131
###begin article-title 132
###xml 36 43 <span type="species:ncbi:9606">patient</span>
###xml 49 64 <span type="species:ncbi:11082">West Nile virus</span>
Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis.
###end article-title 132
###begin article-title 133
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.
###end article-title 133
###begin article-title 134
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 53 56 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Infection of human tonsil histocultures: a model for HIV pathogenesis.
###end article-title 134
###begin p 135
The authors have declared that no competing interests exist.
###end p 135
###begin p 136
This research was supported by the Intramural Research Program of the NIH/NIAID/DIR.
###end p 136

